A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Financial Summary
| Share Statistics | SMDPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,513.1 | $579.1 | 62% |
|
| Shares Out (Mil) | 2.5 | 43.0 | 9% |
|
| Institutional Ownership | 49.9% | 84.3% | 27% |
|
| Float (Mil) | 232.2 | 46.8 | 76% |
|
| Beta | 0.48 | 0.62 | 27% |
|
| Avg Daily Volume (000s) | 0 | 285 | 0% |
|
| Price Change (52-week) |
na | 63.8% | na |
|
| Growth | SMDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (9.4%) | 6.7% | 6% |
|
| Net Income (5yr) | 5.7% | (1.4%) | 48% |
|
| EPS (5yr) | 5.8% | 14.9% | 39 |
|
| Dividends (5yr) | (14.9%) | 0.0% | 0% |
|
| Cash Flow (5yr) | (38.6%) | (14.9%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SMDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,851 | $272 | 66% |
|
| Net Income (TTM) (Mil) | $672 | ($11) | 82% |
|
| EPS (TTM) | $1.692 | ($0.500) | 69% |
|
| Operating Cash Flow (TTM) (Mil) | $451 | ($6) | 70% |
|
| Net Cash Flow (TTM) (Mil) | ($229) | $4 | 9% |
|
| Long-Term Debt (Q1) (Mil) | $1,158 | $7 | 68% |
|
| Enterprise Value (Q1) (Mil) | $5,222 | $522 | 64% |
|
| Valuation | SMDPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SMDPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 56.7% | 65.9% | 69% |
|
| Net Margin | 23.6% | 0.7% | 83% |
|
| ROA | 12.2% | (24.6%) | 91% |
|
| ROE | 46.8% | (19.7%) | 92% |
|
| Liabilities to Assets | 63.6% | 35.5% | 58% |
|
| F-Score | na | 3 | na |
|
Sumitomo Pharma Co., Ltd. did not pass any screens on 7/31/2026.
